DDInter1609 DDInter899
Rivaroxaban is an anticoagulant and the first orally active direct factor Xa inhibitor. Unlike warfarin, routine lab monitoring of INR is not necessary. However there is no antidote available in the event of a major bleed. Only the 10 mg tablet can be taken without regard to food. The 15 mg and 20 mg tablet should be taken with food. FDA approved on July 1, 2011.
Ibrutinib is a small molecule that acts as an irreversible potent inhibitor of Burton's tyrosine kinase. It is designated as a targeted covalent drug and presented as a promising activity in B-cell malignancies in clinical trials. Ibrutinib was developed by Pharmacyclics Inc and was first approved by the FDA in November 2013 for the treatment of mantle cell lymphoma (MCL) under accelerated approval; however, in April 2023, the drug manufacturer withdrew the accelerated approvals for ibrutinib in the US. Ibrutinib was approved by the EMA in October 2014 and by Health Canada in November 2014. It is currently approved for the treatment of various conditions, such as chronic lymphocytic leukemia (CLL), Waldenström's Macroglobulinemia, and chronic graft versus host disease (cGVHD) in August 2017. Notably, ibrutinib became the first FDA-approved cGVHD treatment for children in August 2017.
Rivaroxaban {u} (Compound) resembles {v} (Compound) Linezolid
Rivaroxaban {u} (Compound) binds {v} (Gene) ABCB1
Rivaroxaban {u} (Compound) upregulates {v} (Gene) CDK6
Rivaroxaban {u} (Compound) downregulates {v} (Gene) GJA1
Rivaroxaban {u} (Compound) causes {v} (Side Effect) Pruritus
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Chamomile
Rivaroxaban {u} may cause a minor interaction that can limit clinical effects when taken with {v} Modafinil
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Calaspargase pegol
Rivaroxaban {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Cimetidine
Rivaroxaban {u} may lead to a major life threatening interaction when taken with {v} Regorafenib
Rivaroxaban (Compound) resembles Linezolid (Compound)
Rivaroxaban (Compound) binds ABCB1 (Gene)
Rivaroxaban (Compound) upregulates CDK6 (Gene)
Rivaroxaban (Compound) downregulates GJA1 (Gene)
Rivaroxaban (Compound) causes Pruritus (Side Effect)
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Chamomile
Rivaroxaban may cause a minor interaction that can limit clinical effects when taken with Modafinil
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Calaspargase pegol
Rivaroxaban may cause a moderate interaction that could exacerbate diseases when taken with Cimetidine
Rivaroxaban may lead to a major life threatening interaction when taken with Regorafenib